as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹839.3
Change
-2.7 (-0.32%)
Open
₹844.0
Prev. Close
₹842.0
Day High
₹850.1
Day Low
₹834.25
Volume Analysis
Traded
369,981
Delivered
161,736
Delivery %
43.71%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (30.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (26.4%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹864.04 | ₹857.07 | ₹848.19 | ₹841.22 | ₹832.34 | ₹825.37 | ₹816.49 |
| Fibonacci | ₹857.07 | ₹851.02 | ₹847.27 | ₹841.22 | ₹835.17 | ₹831.42 | ₹825.37 |
| Camarilla | ₹843.66 | ₹842.21 | ₹840.75 | ₹841.22 | ₹837.85 | ₹836.39 | ₹834.94 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-5.51%
1 Week
+2.82%
1 Month
-1.7%
3 Months
-9.88%
6 Months
-16.23%
1 Year
+2.26%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹957.98
Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
14.59%
Net margin 32.86% × asset turnover 0.37x × equity multiplier 1.2x
Company Overview
Sector
Healthcare
Market Cap
₹15,033 Cr
P/E (TTM)
13.1
ROE
17.1%
Book Value
₹515.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Natco Pharma Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 72/100. The strongest factor is Financial Strength (100/100), while Momentum (11/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%). Strong 3-year EPS growth (26.4%).
TopFund Score — Fundamentals Quality
72/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has delivered good profit growth of 28.1% CAGR over last 5 years
- −Tax rate seems low
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Board fixed 1 October 2026 record date for Natco Pharma rights issue entitlement.
Board approved 2-for-21 rights issue at ₹750, raising up to ₹1,279.36 crore; record date October 1, 2026.
Natco Pharma received NSE and BSE in-principle approval for its rights issue on 21 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 |
| Expenses + | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 |
| Operating Profit | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 |
| OPM % | 46.0% | 44.0% | 35.0% | 47.0% | 59.0% | 59.0% | 8.0% | 45.0% | 43.0% | 42.0% | 25.0% | 17.0% | 25.0% |
| Other Income + | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 |
| Interest | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 |
| Depreciation | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 |
| Profit before tax | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 |
| Tax % | 16.0% | 16.0% | 17.0% | 19.0% | 17.0% | 17.0% | 19.0% | 20.0% | 16.0% | 16.0% | 13.0% | -62.0% | 34.0% |
| Net Profit + | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 |
| EPS in Rs | 23 | 21 | 12 | 22 | 37 | 38 | 7 | 23 | 27 | 29 | 8 | 15 | 12 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 825 | 1,042 | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,078 | 3,485 |
| Expenses + | 615 | 777 | 1,337 | 1,256 | 1,300 | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 | 2,234 | 2,617 | 2,433 |
| Operating Profit | 210 | 266 | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,196 | 1,462 | 1,052 |
| OPM % | 25.0% | 25.0% | 34.0% | 42.0% | 38.0% | 30.0% | 30.0% | 14.0% | 35.0% | 44.0% | 50.0% | 36.0% | 30.0% |
| Other Income + | 0 | 12 | 14 | 40 | 130 | 107 | 104 | 99 | 105 | 126 | 354 | 272 | 295 |
| Interest | 32 | 23 | 18 | 15 | 19 | 22 | 13 | 18 | 14 | 19 | 24 | 37 | 46 |
| Depreciation | 47 | 51 | 54 | 66 | 81 | 100 | 117 | 143 | 164 | 187 | 235 | 207 | 196 |
| Profit before tax | 132 | 204 | 624 | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 1,491 | 1,104 |
| Tax % | 1.0% | 24.0% | 22.0% | 22.0% | 22.0% | 19.0% | 24.0% | 16.0% | 17.0% | 17.0% | 18.0% | 8.0% | — |
| Net Profit + | 130 | 156 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,418 | 1,145 |
| EPS in Rs | 8 | 9 | 28 | 38 | 35 | 25 | 24 | 9 | 39 | 78 | 105 | 79 | 64 |
| Dividend Payout % | 12.0% | 14.0% | 24.0% | 22.0% | 18.0% | 27.0% | 22.0% | 48.0% | 14.0% | 12.0% | 6.0% | 6.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 813 | 1,261 | 1,614 | 3,035 | 3,452 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 | 7,571 | 9,185 |
| Borrowings + | 312 | 113 | 222 | 173 | 386 | 316 | 268 | 416 | 167 | 371 | 279 | 714 |
| Other Liabilities + | 226 | 413 | 446 | 470 | 428 | 498 | 403 | 430 | 617 | 682 | 744 | 1,138 |
| Total Liabilities | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 |
| Fixed Assets + | 710 | 710 | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 | 2,698 | 2,803 |
| CWIP | 129 | 212 | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 | 225 | 294 |
| Investments | 2 | 22 | 32 | 76 | 169 | 112 | 304 | 308 | 392 | 539 | 474 | 3,127 |
| Other Assets + | 543 | 878 | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 | 5,234 | 4,850 |
| Total Assets | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 |
| Equity Capital | 33 | 35 | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 93 | 112 | 346 | 464 | 669 | 417 | 299 | 46 | 849 | 1,212 | 1,697 | 1,768 |
| Cash from Investing Activity + | -120 | -176 | -299 | -1,116 | -611 | -175 | -107 | 4 | -465 | -1,026 | -1,436 | -1,987 |
| Cash from Financing Activity + | 29 | 154 | -48 | 651 | -51 | -251 | -186 | 35 | -363 | -247 | -211 | 298 |
| Net Cash Flow | 2 | 90 | -1 | -2 | 7 | -8 | 6 | 85 | 21 | -62 | 50 | 79 |
| CFO/OP | 55 | 60 | 69 | 72 | 107 | 90 | 71 | 36 | 110 | 85 | 94 | 148 |
| Free Cash Flow | -25 | -44 | 66 | 57 | 225 | 81 | 92 | -142 | 674 | 855 | 1,300 | 1,379 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 23.48% | 25.32% | 24.46% | 24.99% | 26.13% | 26.88% | 27.3% | 29.12% | 30.56% | 29.97% | 27.74% | 27.97% |
| Promoters | 49.71% | 49.71% | 49.71% | 49.71% | 49.62% | 49.62% | 49.56% | 49.56% | 49.48% | 49.48% | 49.41% | 49.41% |
| FII | 12.82% | 13.72% | 16.14% | 17.45% | 17.51% | 17.94% | 17.49% | 15.52% | 14.09% | 15.16% | 17.37% | 16.99% |
| DII | 14.01% | 11.26% | 9.69% | 7.86% | 6.75% | 5.59% | 5.64% | 5.81% | 5.87% | 5.39% | 5.46% | 5.63% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Natco Pharma Ltd. (this stock) | 15,033 | 13.1 | 1.63 | 17.1% |
| Molbio Diagnostics Ltd | 15,118 | 60.6 | — | 15.6% |
| Marksans Pharma Limited | 15,269 | 29.6 | 5.05 | 15.2% |
| Syngene International Ltd | 15,287 | 51.6 | 3.16 | 7.78% |
| Vijaya Diagnostic Cen Ltd | 15,590 | 83.2 | 16.28 | 18.3% |
| Dr Agarwals Health Care L | 15,686 | 106.0 | 7.75 | 5.99% |
| Indegene Limited | 14,319 | 34.4 | 4.57 | 14.4% |
Which Mutual Funds Hold Natco Pharma Ltd.?
Frequently Asked Questions about Natco Pharma Ltd.
Natco Pharma Ltd. (NATCOPHARM) closed at ₹839.3 on NSE on 25 September 2026, down 2.7 (0.32%) from the previous close.
Natco Pharma Ltd. trades on the NSE (National Stock Exchange of India) under the symbol NATCOPHARM.
Natco Pharma Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 13.1.
Natco Pharma Ltd. has a dividend yield of 0.6%.
Natco Pharma Ltd.'s 52-week high is ₹1,227.0 and its 52-week low is ₹789.0.
Natco Pharma Ltd. has a market capitalisation of ₹15,033 crore.
Natco Pharma Ltd. has a TopFund Quality Score of 72/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Natco Pharma Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.